abstract |
Pharmaceutical composition comprising an alpha-MSH analogue which is an alpha-MSH derivative that exhibits agonist activity for the melanocortin-1 receptor (MCR1), the receptor to which alpha-MSH binds to initiate melanin production within of a melanocyte, for use in the treatment or prevention of vitiligo in a human subject where the pharmaceutical composition is administered subcutaneously in a sustained release delivery system. |